Table 1.

Categorization, molecular information and culture conditions of 84 breast cancer cell lines, and the clinical features of tumors where they derive.

Cell lines	ER	PR	HER2	BRCA1 Mutation	Subtype	Series	Basic Medium	Tumor	Source	References
BT483	+	+/-	-	WT	LA	BT	RPMI	IDC	L	1, 5, 6, 8, 10
CAMA1	+	+/-	-	WT	LA	NA	DMEM	AC	L	1, 5, 6, 10
EFM19	+	+	-	ND	LA	EFM	RPMI	IDC	L	8, 10
HCC1428	+	+	-	ND	LA	HCC	RPMI	AC	L	5, 8
HCC712	+	+/-	-	ND	LA	HCC	RPMI	DC	L	8
IBEP2	+	-	-	ND	LA	NA	DMEM	IDC	L	10
KPL1	+	-	-	ND	LA	NA	RPMI	IDC	L	10, 61
LY2	+	-	-	ND	LA	NA	DMEM	IDC	L	5
MCF7	+	+	-	WT	LA	MCF	RPMI, DMEM	IDC	L	1, 5, 6, 8, 10, 58
MDAMB134	+	-	-	ND	LA	MDA	RPMI	IDC	L	8
MDAMB134VI	+	-	-	WT	LA	MDA	DMEM	IDC	L	1, 5, 6, 10
MDAMB175	+	-	-	ND	LA	MDA	RPMI	IDC	L	8
MDAMB175VII	+	-	-	WT	LA	MDA	DMEM	IDC	L	1, 5, 6, 10
MDAMB415	+	+/-	-	WT	LA	MDA	DMEM	AC	L	5, 6, 10
T47D	+	+	-	WT	LA	NA	RPMI	IDC	L	1, 5, 6, 8, 10
ZR751	+	+/-	-	WT	LA	ZR75	RPMI	IDC	L	1, 5, 6, 8, 10
ZR75B	+	-	-	ND	LA	ZR75	RPMI	NA	L	5
BSMZ	+	+	+	ND	LB	NA	RPMI	IDC	L	10, 19
BT474	+	+	+	WT	LB	BT	RPMI	IDC	L	1, 5, 6, 8, 10
EFM192A	+	+	+	ND	LB	EFM	RPMI	AC	L	8
IBEP1	-	+	+	ND	LB	IBEP	DMEM	IDC	L	10
IBEP3	-	+	+	ND	LB	IBEP	DMEM	IDC	L	10
MDAMB330	+	-	+	WT	LB	MDA	RPMI	ILC	L	1, 6, 10
MDAMB361	+	+/-	+	WT	LB	MDA	RPMI, DMEM	AC	L	1, 5, 6, 8, 10
UACC812	+	+/-	+	WT	LB	UACC	RPMI, DMEM	IDC	L	1, 5, 6, 8, 10
ZR7527	+	-	+	WT	LB	ZR75	RPMI	IDC	L	60
ZR7530	+	-	+	WT	LB	ZR75	RPMI	IDC	L	1, 5, 6, 8, 10
21MT1	-	+/-	+	ND	H	21	α-MEM/DFC1	IDC	L	15
21MT2	-	+/-	+	ND	H	21	α-MEM/DFC1	IDC	L	15
21NT	-	+/-	+	ND	H	21	α-MEM/DFC1	IDC	L	15
21PT	-	+/-	+	ND	H	21	α-MEM/DFC1	IDC	L	15
AU565	-	-	+	WT	H	NA	RPMI	AC	L	5, 10, 58
HCC1008	-	-	+	ND	H	HCC	RPMI	IDC	L	12
HCC1569	-	-	+	WT	H	HCC	RPMI	MC	L	1, 5, 8
HCC1954	-	-	+	WT	H	HCC	RPMI	DC	L	1, 5, 8
HCC202	-	-	+	WT	H	HCC	RPMI	DC	L	1, 5, 8
HCC2218	-	-	+	ND	H	HCC	RPMI	DC	L	8
HH315	-	-	+	ND	H	HH	RPMI	C	L	10, 59
HH375	-	-	+	ND	H	HH	RPMI	C	L	10, 59
KPL-4	-	-	+	WT	H	KPL	DMEM	IDC	L	10, 62
MDAMB453	-	-	+	WT	H	MDA	RPMI, DMEM	AC	L	1, 5, 6, 8, 10
OCUB-F	-	-	+	WT	H	NA	RPMI	NA	L	1, 6
SKBR3	-	-	+	WT	H	SKBR	RPMI, McCoys	AC	L	1, 5, 6, 8, 10
SKBR5	-	-	+	WT	H	SKBR	RPMI	AC	L	1, 6
SUM190PT	-	-	+	WT	H	SUM	Ham's F12	Inf	L	1, 5, 6, 8
SUM225CWN	-	-	+	WT	H	SUM	Ham's F12	IDC	L	1, 5, 6
UACC893	-	-	+	WT	H	UACC	RPMI	IDC	L	1, 6, 8, 10
BT20	-	-	-	WT	TNA	BT	RPMI, DMEM	IDC	L	1, 5, 6, 8, 10
CAL148	-	-	-	WT	TNA	CAL	DMEM	AC	D	71
DU4475	-	-	-	WT	TNA	NA	RPMI	IDC	D	1, 6, 10
EMG3	-	-	-	ND	TNA	NA	DMEM	IDC	L	25, 48, 57
HCC1143	-	-	-	ND	TNA	HCC	RPMI	DC	L	1, 5, 8
HCC1187	-	-	-	ND	TNA	HCC	RPMI	DC	L	5, 8
HCC1599	-	-	-	ND	TNA	HCC	RPMI	DC	L	8
HCC1806	-	-	-	ND	TNA	HCC	RPMI	SqC	L	1, 8
HCC1937	-	-	-	MU	TNA	HCC	RPMI	DC	L	1, 5, 6, 8
HCC2157	-	-	-	ND	TNA	HCC	RPMI	DC	L	5, 8
HCC3153	-	-	-	MU	TNA	HCC	RPMI	DC	L	5, 8
HCC70	-	-	-	WT	TNA	HCC	RPMI	DC	L	1, 5, 8
HMT3522	-	-	-	WT	TNA	HMT	DMEM, F12	B	L	49
KPL-3C	-	-	-	ND	TNA	KPL	RPMI	IDC	D	10, 36
MA11	-	-	-	ND	TNA	NA	DMEM	ILC	D	10, 37, 63
MDAMB435	-	-	-	WT	TNA	MDA	DMEM	AC	L	1, 5, 6, 10
MDAMB436	-	-	-	MU	TNA	MDA	RPMI, L15	AC	L	1, 5, 6, 8, 10
MDAMB468	-	-	-	WT	TNA	MDA	RPMI, L15	AC	L	1, 5, 6, 8, 10
MFM223	-	-	-	WT	TNA	NA	MEM	C	D	71
SUM185PE	-	-	-	WT	TNA	SUM	Ham's F12	DC	L	1, 5, 6
SUM229PE	-	-	-	WT	TNA	SUM	RPMI	DC	L	1, 6
BT549	-	-	-	WT	TNB	BT	RPMI	IDC	L	1, 5, 6, 8, 10
CAL120	-	-	-	WT	TNB	CAL	DMEM	AC	D	71
CAL51	-	-	-	WT	TNB	CAL	DMEM	AC	D	71
CAL851	-	-	-	WT	TNB	CAL	DMEM	AC	D	71
HCC1395	-	-	-	ND	TNB	HCC	RPMI	DC	L	1, 8
HCC1739	-	-	-	ND	TNB	HCC	RPMI	DC	D	12
HCC38	-	-	-	ND	TNB	HCC	RPMI	DC	L	1, 5, 8
HDQ-P1	-	-	-	MU	TNB	NA	DMEM	IDC	D	71
Hs578T	-	-	-	WT	TNB	NA	RPMI, DMEM	IDC	L	1, 5, 6, 8, 10
MDAMB157	-	-	-	WT	TNB	MDA	RPMI, DMEM	MC	L	1, 5, 6, 8, 10
MDAMB231	-	-	-	WT	TNB	MDA	RPMI, DMEM	AC	L	1, 5, 6, 8, 10
SKBR7	-	-	-	WT	TNB	SKBR	RPMI	AC	L	1, 6
SUM102PT	-	-	-	WT	TNB	SUM	Ham's F12	IDC	L	1, 6, 8
SUM1315M02	-	-	-	MU	TNB	SUM	Ham's F12	IDC	L	1, 5, 6
SUM149PT	-	-	-	MU	TNB	SUM	Ham's F12	InfDC	L	1, 5, 6, 8
SUM159PT	-	-	-	WT	TNB	SUM	Ham's F12	AnC	L	1, 5, 6

The status on ER, PR and HER2 are the primary features used for breast cancer cell line subtyping ¹, ⁵, ⁶, ⁸, ¹⁰, ¹², ¹⁵, ¹⁹, ²⁵, ³⁶, ³⁷, ⁴⁸, ⁴⁹, ⁵⁷-⁶³. BRCA1 mutation status is annotated for the ease of sporadic core basal tumor modeling, where MU represents cell lines with 'BRCA1 mutation', WT means 'wild type', and ND is short for 'not decided' ⁴, ⁶, ⁶⁴, ⁶⁵. We categorize these cell lines into luminal A (LA), luminal B (LB), HER2 positive (H), Triple negative A (TNA) and Triple negative B (TNB), according to literature available subtyping suggestions (L) or derived information from the original article where they are established (D). Such information are provided in the 'Subtype' and 'Source' columns, respectively, with references listed in column 'References'. The 'Series' column shows which cell line series each cell line comes from which are conventionally given by the establisher and represents, e. g. , the place where the cell line is created ¹², ¹⁴, ¹⁵, ⁴⁹, ⁶⁰, ⁶⁶-⁷⁰. 'Basic Medium' shows the common or suggested medium for the cultivation of each cell line, which may need the addition of other elements and does not eliminate the feasibility of other medium ¹, ⁵, ⁸, ¹⁵, ⁶⁶. The 'Tumor' column shows the clinical property of the tumor where the cell lines are derived, with the following symbolic representations, i. e. , AC is 'adenocarcinoma', AnC is 'anaplastic carcinoma', B is 'benign tumor', C is 'carcinoma', CS is 'carcinosarcoma', DC is 'ductal carcinoma', IDC is 'invasive ductal carcinoma', ILC is 'invasive lobular carcinoma', InfC is 'inflammatory carcinoma', InfDC is 'inflammatory ductal carcinoma', MC is 'medullary carcinoma', SqC is 'squamous carcinoma', and NA means such information is not available ⁵, ⁸, ¹⁰, ¹⁵.